Wedbush Maintains Outperform on Omega Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has maintained an Outperform rating on Omega Therapeutics (NASDAQ:OMGA), but lowered the price target from $19 to $12.
November 10, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Omega Therapeutics' price target has been lowered from $19 to $12 by Wedbush, although the Outperform rating is maintained.
The lowering of the price target by a significant margin could potentially lead to a decrease in the stock price in the short term. However, the maintained Outperform rating indicates that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100